Sustained Effectiveness of a Fixed-Dose Combination of Artesunate and Amodiaquine in 480 Patients with Uncomplicated Plasmodium falciparum Malaria in Côte d'Ivoire

Serge Brice Assi, Abouo Franklin Nguessan, Yapo Thomas Aba, André Offianan Toure, Hervé Menan, Jean Claude Yavo, Koffi Moïse San, Emmanuel Bissagnéné, Stephan Duparc, Valérie Lameyre, Mea Antoine Tanoh, Serge Brice Assi, Abouo Franklin Nguessan, Yapo Thomas Aba, André Offianan Toure, Hervé Menan, Jean Claude Yavo, Koffi Moïse San, Emmanuel Bissagnéné, Stephan Duparc, Valérie Lameyre, Mea Antoine Tanoh

Abstract

The objective of this study was to monitor the effectiveness of artesunate-amodiaquine fixed-dose combination tablets (ASAQ Winthrop®) in the treatment of uncomplicated Plasmodium falciparum malaria in Côte d'Ivoire. Two enrolment periods (November 2009 to May 2010 and March to October 2013) were compared using an identical design. Subjects with proven monospecific P. falciparum infection according to the WHO diagnostic criteria were eligible. 290 patients during each period received a dose of ASAQ Winthrop tablets appropriate for their age. The primary outcome measure was PCR-corrected adequate clinical and parasitological response at Day 28 in the per protocol population (255 in Period 1 and 240 in Period 2). This was achieved by 95.7% of patients during Period 1 and 96.3% during Period 2. Over 95% of patients were afebrile at Day 3 and complete parasite clearance was achieved at Day 3 in >99% of patients. Nineteen adverse events in nineteen patients were considered as possibly related to treatment, principally vomiting, abnormal liver function tests, and pruritus. There was no evidence for loss of effectiveness over the three-year period in spite of strong drug pressure. This trial was registered in the US Clinical Trials Registry (clinical.trials.gov) under the identifier number NCT01023399.

Figures

Figure 1
Figure 1
Trial profile. Percentages are calculated with respect to the previous line in the flow chart. FU: follow-up; ITT: intention to treat; PP: per protocol.
Figure 2
Figure 2
Adequate clinical and parasitological response (ACPR) rates at Day 28 after PCR correction in the per protocol (PP) and intention-to-treat (ITT) populations. ACPR rates are presented with their 95% confidence limits.

References

    1. White N. J., Pukrittayakamee S., Hien T. T. Malaria. The Lancet. 2013;383(9918):723–735. doi: 10.1016/S0140-6736(13)60024-0.
    1. World Health Organization. Guidelines for the Treatment of Malaria. Geneva, Switzerland: WHO Press; 2006.
    1. World Health Organization. Guidelines for the Treatment of Malaria. 3rd. Geneva, Switzerland: WHO Press; 2015.
    1. Taylor S. M., Parobek C. M., DeConti D. K., et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. The Journal of Infectious Diseases. 2015;211(5):680–688. doi: 10.1093/infdis/jiu467.
    1. Conrad M. D., Bigira V., Kapisi J., et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS ONE. 2014;9(8, article e105690) doi: 10.1371/journal.pone.0105690.
    1. Ashley E. A., Dhorda M., Fairhurst R. M., et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. The New England Journal of Medicine. 2014;371(5):411–423.
    1. Ariey F., Witkowski B., Amaratunga C., et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50–55. doi: 10.1038/nature12876.
    1. Lemnge M., Alifrangis M., Kafuye M. Y., et al. High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, northeastern Tanzania. The American Journal of Tropical Medicine and Hygiene. 2006;75(2):188–193.
    1. Eyase F. L., Akala H. M., Ingasia L., et al. The Role of Pfmdr1 and Pfcrt in changing Chloroquine, Amodiaquine, Mefloquine and Lumefantrine susceptibility in Western-Kenya P. falciparum samples during 2008–2011. PLoS ONE. 2013;8(5, article e64299) doi: 10.1371/journal.pone.0064299.
    1. Talisuna A. O., Karema C., Ogutu B., et al. Mitigating the threat of artemisinin resistance in Africa: Improvement of drug-resistance surveillance and response systems. The Lancet Infectious Diseases. 2012;12(11):888–895. doi: 10.1016/S1473-3099(12)70241-4.
    1. Griffin A. New once a day, fixed dose antimalarial is now available for adults and children. BMJ (Clinical research ed.) 2007;334(7591, article 443)
    1. Faucher J.-F., Aubouy A., Adeothy A., et al. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether- lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: A randomized effectiveness noninferiority trial. The Journal of Infectious Diseases. 2009;200(1):57–65. doi: 10.1086/599378.
    1. Ndiaye J. L., Randrianarivelojosia M., Sagara I., et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malaria Journal. 2009;8(1, article 125) doi: 10.1186/1475-2875-8-125.
    1. Sirima S. B., Tiono A. B., Gansané A., et al. The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malaria Journal. 2009;8(1, article 48) doi: 10.1186/1475-2875-8-48.
    1. Ndiaye J.-L. A., Faye B., Gueye A., et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: A randomized, open-label trial. Malaria Journal. 2011;10, article 237 doi: 10.1186/1475-2875-10-237.
    1. The Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in african children: a randomized trial. PLoS Medicine. 2011;8(11, article e1001119) doi: 10.1371/journal.pmed.1001119.
    1. Schramm B., Valeh P., Baudin E., et al. Efficacy of artesunate-amodiaquine and Artemether-Lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malaria Journal. 2013;12, article 251 doi: 10.1186/1475-2875-12-251.
    1. Schramm B., Valeh P., Baudin E., et al. Tolerability and safety of artesunate-amodiaquine and artemether- lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: Two open-label, randomized trials in Nimba County, Liberia. Malaria Journal. 2013;12(1, article 250) doi: 10.1186/1475-2875-12-250.
    1. Yeka A., Lameyre V., Afizi K., et al. Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children. PLoS ONE. 2014;9(12, article e113311) doi: 10.1371/journal.pone.0113311.
    1. Bompart F., Kiechel J.-R., Sebbag R., Pecoul B. Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: Lessons learned from the ASAQ Winthrop experience. Malaria Journal. 2011;10, article 143 doi: 10.1186/1475-2875-10-143.
    1. Assi S.-B., Aba Y. T., Yavo J. C., et al. Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d’Ivoire. Malaria Journal. 2017;16(1):1–12. doi: 10.1186/s12936-016-1655-1.
    1. World Health Organization. Methods for Surveillance of Antimalarial Efficacy. Geneva, Switzerland: WHO Press; 2009.
    1. World Health Organization. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva, Switzerland: WHO Press; 2003.
    1. World Health Organization. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. Geneva, Switzerland: WHO Press; 2008.
    1. Espié E., Lima A., Atua B., et al. Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: A randomized non-inferiority trial. Malaria Journal. 2012;11, article 174 doi: 10.1186/1475-2875-11-174.
    1. Gbotosho G. O., Sowunmi A., Happi C. T., Okuboyejo T. M. Therapeutic efficacies of artemisinin-based combination therapies in nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments. The American Journal of Tropical Medicine and Hygiene. 2011;84(6):936–943. doi: 10.4269/ajtmh.2011.10-0722.
    1. Shayo A., Mandara C. I., Shahada F., Buza J., Lemnge M. M., Ishengoma D. S. Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. Malaria Journal. 2014;13(1, article 376) doi: 10.1186/1475-2875-13-376.
    1. World Health Organization. Methods for Surveillance of Antimalarial Drug Efficacy. Geneva, Switzerland: WHO; 2009.
    1. Toure O. A., Assi S. B., N'Guessan T. L., et al. Open-label, randomized, non-inferiority clinical trial of artesunate-Amodiaquine versus artemetherlumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire. Malaria Journal. 2014;13(1, article 439) doi: 10.1186/1475-2875-13-439.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren